We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Construction of the "Patient-Centered"Molecular Pathology Diagnostic Center

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified March 2011 by Taipei Medical University WanFang Hospital.
Recruitment status was:  Active, not recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT01311388
First Posted: March 9, 2011
Last Update Posted: March 9, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Taipei Medical University WanFang Hospital
  Purpose
The investigators want to achieve the goal of diagnosis in early phase, accurate treatment and existence for a long period in order to screen in early phase, diagnose in clinical trial, choose treatment and evaluate prognosis of cancers by establishing molecular pathology tools.

Condition
Cancer

Study Type: Observational
Study Design: Time Perspective: Retrospective
Official Title: Construction of the "Patient-Centered"Molecular Pathology Diagnostic Center

Further study details as provided by Taipei Medical University WanFang Hospital:

Estimated Enrollment: 1500
Study Start Date: August 2010
Estimated Study Completion Date: December 2013
Detailed Description:

This research is going to discuss the biomarker expression of common malignant neoplasm (tumor)among Taiwanese, such as large intestine rectal cancer, breast cancer, prostate gland cancer, lung cancer, oral cancer, gastric cancer, liver cancer, cervical cancer, cancer of the womb, ovarian cancer, carcinoma of urinary bladder, kidney cancer and so on.

The investigators hope to find the biomarker of common tumors among Taiwanese in order to develop the tools of tumor screening, diagnosis, treatment methods and prediction prognosis

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
cancer patients
Criteria

Inclusion Criteria:

  • above 20 years old
  • all kinds of cancer patients

Exclusion Criteria:

  • under 20 years old
  • none cancer patients
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01311388


Locations
Taiwan
TMU-CECR
Taipei, Taiwan
Sponsors and Collaborators
Taipei Medical University WanFang Hospital
Investigators
Principal Investigator: Wen-Ta Chiu TMU-CECR
  More Information

Responsible Party: Wen-Ta Chiu, Taipei Medical University-Center of Excellence For Cancer Research, TMU-CECR
ClinicalTrials.gov Identifier: NCT01311388     History of Changes
Other Study ID Numbers: 99049
First Submitted: March 6, 2011
First Posted: March 9, 2011
Last Update Posted: March 9, 2011
Last Verified: March 2011

Keywords provided by Taipei Medical University WanFang Hospital:
cancer